New Tests Show Know Labs Bio-RFID™ Technology Delivers Blood Glucose Readings Comparable to FDA-Cleared Devices

New Tests Show Know Labs Bio-RFID™ Technology Delivers Blood Glucose Readings Comparable to FDA-Cleared Devices

Irvine, CA — October 6, 2021 – Boustead Securities, LLC (“Boustead”) client Know Labs, Inc. (OTCQB: KNWN), an emerging leader in noninvasive medical diagnostics, today published a new report on its non-invasive platform technology, Bio-RFIDTM, comparing its clinical accuracy to FDA-cleared glucose monitoring devices that are currently available in the market.

Read Full Story here

No Comments

Post a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.